Navigation Links
Clinical Genomics Extends Strategic Alliance for Colorectal Cancer Testing Development with Quest Diagnostics
Date:7/12/2011

SYDNEY, July 12, 2011 /PRNewswire/ -- Australian biotech company Clinical Genomics Pty Ltd today announced agreement with Quest Diagnostics, the world's leading provider of diagnostic testing, information and services, to extend a strategic alliance between the two companies related to Clinical Genomics' proprietary biomarkers for colorectal cancer and precancerous colorectal cancer tumors. Under the agreement, Quest Diagnostics will make milestone payments to Clinical Genomics for the development and validation of new molecular blood tests for the early detection of colorectal cancer. Clinical Genomics has been awarded payments after successfully achieving key research and development goals. Additional terms were not disclosed.

"There is a growing need for noninvasive blood tests that can aid the detection of colorectal cancer or precancerous polyps in the earliest, most treatable stages," said Dr. Lawrence LaPointe, CEO of Clinical Genomics. "Quest Diagnostics is leading the industry in developing blood and fecal immunochemical tests for aiding colorectal cancer detection. By extending our alliance with Quest Diagnostics, we will continue to transition Clinical Genomics' research of colorectal cancer gene targets into clinical testing services for the large, underserved market of the United States and other countries."

Quest Diagnostics offers a broad menu of colorectal cancer tests, including the ColoVantage(TM) blood test for aiding the detection of colon cancer for patients in the United States, and the InSure(R) fecal immunochemical test (FIT), manufactured by the company's Sydney-based Enterix Inc. business and available in Australia and the United States.

Colorectal cancer is the second most common cause of cancer death of both men and women in the United States, according to the American Cancer Society. Although five-year survival for detected early-stage colorectal cancer is about 90 percent, some patients resist colonoscopy and other methods and never get screened. According to results of a recent poll co-sponsored by Quest Diagnostics, three in four people would be more likely to be screened for colon cancer if a blood test were available.

About Clinical Genomics

Clinical Genomics is a Sydney-based biotechnology company formed in 2006 to exploit the patented and patent-pending gene expression biomarkers for colorectal cancer discovered by its founders and Flinders University in 2001. Clinical Genomics continues to work closely with Flinders University and the Commonwealth Scientific and Industrial Research Organisation (CSIRO) in Australia to advance the development of products that will improve the detection and management of colorectal neoplasia.  Additional information is available at: www.clinicalgenomics.com

Further Information:
Dr. Lindsay Collinson
Clinical Genomics Pty Ltd
Ph: +61 2 9888 9065
E: Lindsay.collinson@clinicalgenomics.com


'/>"/>
SOURCE Clinical Genomics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Family Foundation of Business Leader Invests $4.55 Million in Northwest Biotherapeutics for Promising Clinical Trials in the US and Europe
2. "Pure" Human Blood Stem-Cell Discovery Opens Door to Expanding Cells for More Clinical Use
3. Merrimack Announces Presentation of Preclinical Data at the 14th World Conference on Lung Cancer
4. Inovio Pharmaceuticals Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial
5. Celladon Corporation Announces Publication of Advanced Heart Failure Clinical Trial Results With MYDICAR® Enzyme Replacement Therapy in the Journal Circulation
6. AltheaDx Incorporates Next-Generation Sequencing Into Its Clinical Testing Pipeline.
7. Nile Therapeutics Provides Update on Ongoing Phase I Clinical Trial of Cenderitide
8. Drug Dropout in Clinical Trials Is at Unsustainable Levels, According to Thomson Reuters, CMR International
9. ERA-EDTA Congress 2011: Late Breaking Clinical Trials I
10. ClinicalRM (formerly CRM) Awarded $97MM U.S. Army Contract to Support Military Clinical Research for the Warfighter
11. MDOUTLOOK® 4th Annual Quick Polls From ASCO 2011: Report on Clinical Impact of New Developments in Cancer Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... Jan. 16, 2017  Eurofins Genomics today announced the ... more customers to receive their primers in a shorter ... in quality found with other providers. Express oligos are ... at no additional fee. Researchers ... studies, including DNA sequencing, genotyping, site-directed mutagenesis, and cloning. ...
(Date:1/13/2017)... DUBLIN , Jan 13, 2017 Research and ... report to their offering. ... The global biopolymers market to grow at a CAGR of 16.83% ... scenario and the growth prospects of the global biopolymers market for 2017-2021. ... the sale of sales of biopolymer products. The report also includes a ...
(Date:1/12/2017)... ... January 12, 2017 , ... ... IS A SUCCESS , VTI, Vertebral Technologies, Inc., announces the successful outcome ... expandable device. Since September 2016, VTI (Vertebral Technologies, Inc.) has partnered with ...
(Date:1/12/2017)... ... January 12, 2017 , ... After her brain ... doctors gave her only a few months to live. Now a paper publishing ... stabilized Rosendahl’s disease and increased both the quantity and quality of her life: ...
Breaking Biology Technology:
(Date:1/6/2017)... 5, 2017  Delta ID Inc., a leader in ... for automotive at CES® 2017. Delta ID has collaborated ... demonstrate the use of iris scanning as a secure, ... driver in a car, and as a way to ... Delta ID and Gentex will demonstrate (booth ...
(Date:12/22/2016)... , Dec. 20, 2016  As part of its longstanding ... leading personal genetics company, recently released its latest children,s book, ... The book focuses on the topics of inheritance and variation ... Standards (NGSS) taught in elementary school classrooms in the US. ... series by illustrator Ariana Killoran , whose previous book ...
(Date:12/19/2016)... , España y TORONTO , 19 de diciembre ... Northern Biologics Inc. que permitirá el desarrollo acelerado de MSC-1, un ... en varios tipos de tumor en 2017, con múltiples sitios previstos ... ... clase con objetivo en el factor inhibidor de leucemia (LIF), una ...
Breaking Biology News(10 mins):